Skip to main content
. 2020 Feb 10;130(3):1168–1184. doi: 10.1172/JCI126361

Figure 8. MTEP and U73122 improve D1 receptor–dependent dyskinesias in WT mice, but have no effect in mGluR5KD-D1 mice.

Figure 8

(A and B) L-DOPA–induced AIMs in WT mice. (A) Time course of AIMs (n = 11; repeated-measures [RM] 2-way ANOVA, treatment: F(2,20) = 13.6, P < 0.001; time: F(9,90) = 45.87, P < 0.001; interaction: F(18,180) = 4.49, P < 0.001). (B) Peak AIMs (n = 11; Friedman test (Fr) = 16.55, P < 0.001). (C and D) SKF38393-induced AIMs in WT. (C) Time course of AIMs (n = 11; RM 2-way ANOVA, treatment: F(2,20) = 17.28, P < 0.001; time: F(8,80) = 23, P < 0.001; interaction: F(16,160) = 5.05, P < 0.001). (D) Peak AIMs (n = 11; Fr = 11.45, P < 0.01). (E and F) Quinpirole-induced AIMs in WT. (E) Time course of AIMs (n = 11; RM 2-way ANOVA, treatment: F(2,20) = 1.48, P = 0.25; time: F(8,80) = 148.6, P < 0.001; interaction: F(16,160) = 2.16, P < 0.01). (F) Peak AIMs (n = 11; Fr = 4.97, P > 0.05). (G and H) L-DOPA–induced AIMs in mGluR5KD-D1 mice. (G) Time course of AIMs (n = 10; RM 2-way ANOVA, treatment: F(2,18) = 3.92, P = 0.31; time: F(9,81) = 20.56, P < 0.001; interaction: F(18,162) = 2.04, P < 0.05). (H) Peak AIMs (n = 10; Fr = 7.4, P < 0.05). (I and J) SKF38393-induced AIMs in mGluR5KD-D1 mice. (I) Time course of AIMs (n = 10; RM 2-way ANOVA, treatment: F(2,18) = 5.42, P < 0.05; time: F(8,72) = 17.33, P < 0.001; interaction: F(16,144) = 3.23, P < 0.001). (J) Peak AIMs (n = 10; Fr = 5, P > 0.05). (K and L) Quinpirole-induced AIMs in mGluR5KD-D1 mice. (K) Time course of AIMs (n = 10; RM 2-way ANOVA, treatment: F(2,18) = 2.51, P = 0.12; time: F(8,72) = 178.8, P < 0.001; interaction: F(16,144) = 2.98, P < 0.001). (L) Peak AIMs (n = 10; Fr = 1.4, P > 0.05). Bonferroni’s test or Dunn’s test (for peak AIMs): *P < 0.05, **P < 0.01 and ***P < 0.001 vs. DA receptor agonist + vehicle; #P < 0.05 and ###P < 0.001 vs. DA receptor agonist + MTEP.